Logo Image

Authors

Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: [email protected]

Latest Article

ECOG Status of 1 Associated With Poorer PROs in Gastric/GEJ Cancer

ECOG performance status of 1 was linked with worse patient-reported outcomes in patients with gastric or gastroesophageal junction adenocarcinoma.

Oncology Nursing News Staff
Latest Article

Navigating Efficacy Benchmarks and Real-World Outcomes in Metastatic Colorectal Cancer

Julie Elliott, MS, PA-C, reviewed clinical trial data, compared efficacy across third-line regimens, and discussed how real-world outcomes align across third-line treatment options.

Sabrina Serani

Sabrina Serani is a senior editor for Targeted Oncology.

Latest Article

Setidegrasib Demonstrates Clinical Activity and Manageable Safety in KRAS G12D+ NSCLC

Explore phase 1 data for setidegrasib, a novel KRAS G12D-targeted protein degrader showing antitumor activity and manageable infusion-related reactions in patients with advanced NSCLC.

Lisa Hwa Christenson, APRN, DNP, CNP, FAPO
Latest Article

Relapsed/Refractory Multiple Myeloma Treatment: Personalized Sequencing

Treatment for patients with R/R multiple myeloma should be based on the individual patient and their history, said Lisa Hwa Christenson, DNP, APRN, CNP.

Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Latest Article

Frontline Nivolumab/Ipilimumab Sustains Efficacy, Safety in Unresectable HCC

The frontline combination of nivolumab and ipilimumab demonstrated long-term safety and efficacy in patients with unresectable hepatocellular carcinoma.

Sandy Srinivas, MD
Latest Article

Choosing the Optimal ARPI for Older Patients With Prostate Cancer

Sandy Srinivas, MD, of Stanford Cancer Center, discusses the critical role of patient selection, chemo-fitness, and managing comorbidities when selecting ARPI doublets for older patients with prostate cancer.

Rebecca W. Repetti, NP